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Abstract: Fibromyalgia (FM) is a heterogeneous and complex syndrome; different studies have tried
to describe subgroups of FM patients, and a 4-cluster classification based on the Fibromyalgia Impact
Questionnaire-Revised (FIQR) has been recently validated. This study aims to cross-validate this
classification in a large US sample of FM patients. A pooled sample of 6280 patients was used.
First, we computed a hierarchical cluster analysis (HCA) using FIQR scores at item level. Then, a
latent profile analysis (LPA) served to confirm the accuracy of the taxonomy. Additionally, a cluster
calculator was developed to estimate the predicted subgroup using an ordinal regression analysis.
Self-reported clinical measures were used to examine the external validity of the subgroups in part of
the sample. The HCA yielded a 4-subgroup distribution, which was confirmed by the LPA. Each
cluster represented a different level of severity: “Mild–moderate”, “moderate”, “moderate–severe”,
and “severe”. Significant differences between clusters were observed in most of the clinical measures
(e.g., fatigue, sleep problems, anxiety). Interestingly, lower levels of education were associated with
higher FM severity. This study corroborates a 4-cluster distribution based on FIQR scores to classify
US adults with FM. The classification may have relevant clinical implications for diagnosis and
treatment response.
Keywords: Fibromyalgia Impact Questionnaire Revised; Fibromyalgia; clusters; latent profile analy-
sis; hierarchical cluster analysis
1. Introduction
Fibromyalgia (FM) is a chronic pain condition that affects approximately 2% of the
general population worldwide [1]. Patients present a wide range of symptoms, primarily
chronic widespread pain, allodynia and hyperalgesia, stiffness, fatigue, sleep problems,
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impaired balance, cognitive difficulties, and distress [2,3]. Moreover, FM often co-occurs
with psychiatric disorders and other conditions characterized by central sensitization [4,5].
Currently, FM management focuses on symptom reduction through prescription of dif-
ferent medications and recommendation of psychotherapies and other non-pharmacological
interventions such as aerobic exercise [6]. However, none of these provide more than a
modest impact on symptom relief and quality of life [7–10]. Heterogeneity in treatment
response may obscure positive findings for some people with FM; thus, describing subtypes
could be a valuable contribution for moving toward the ability to match treatments to
individuals based on their personal characteristics and clinical status.
There has been a great deal of work attempting to identify FM subgroups [11]. How-
ever, not all studies have used the same methodology; while some have used self-report
measures, others have included variables such as the body mass index or biological mea-
sures to classify FM [12]. There are many approaches to identifying FM subgroupings, each
holding potential heuristic and clinical value.
De-Souza et al. [13] used the Fibromyalgia Impact Questionnaire (FIQ) [14] as a cluster-
derivation measure. This approach to FM classification is clinically relevant and can be
easily implemented in real world clinical practice. De-Souza et al. observed two sub-
groups, mainly differentiated by the impact of morning tiredness, anxiety, and depressive
symptoms. Subsequent studies used this approach in FM samples from different coun-
tries [15–17], observing additional between-cluster differences in number of comorbidities,
health-related quality of life, and sleep quality.
More recently, the revised version of the questionnaire (i.e., FIQR) [18] has been
used to classify subtypes of patients in Italy [19] and Spain [11]. The FIQR represents a
refinement of the original FIQ; the scoring system is easier, and the third domain (i.e.,
Symptom severity) includes new items. Perhaps due to these modifications, the clustering
studies conducted in Italy and Spain based on the FIQR have found more than two clusters.
Salaffi et al. [19] found three subgroups in a sample of 353 Italian FM patients: “Mild”,
“moderate”, and “severe”. However, no other measures were included in the study to
assess the external validity of this classification. Pérez-Aranda et al. [11] analyzed a sample
of Spanish FM patients (N = 947) and found 4 clusters: “mild-moderate”, “moderate”,
“moderate-severe”, and “severe”. These clusters presented significant differences in clinical
variables (e.g., anxiety, depressive symptoms, fibrofog, and stress) and in indirect costs,
reflecting the socioeconomic impact of severity of FM. This four-cluster classification has
not been replicated in other cultures, so its global applicability remains unclear.
The present study provides a cross-validation of the four-cluster classification based
on FIQR scores in a large US sample (N = 6280) of individuals with FM. In addition, we
developed a publicly accessible online cluster calculator to make the present results easily
implementable in US clinical settings.
2. Materials and Methods
2.1. Participants
For the purpose of this study, we pooled two large US samples of individuals with FM.
One subsample consists of 1639 adult FM patients who participated in a study to evaluate
Patient Reported Outcomes Measurement Information System (PROMIS) measures in
FM [20]. All participants were members of the National Fibromyalgia Association (NFA), a
patient advocacy organization. Most of the participants were female (96.9%), middle-aged
(M = 52.8, SD = 10.57, Range = 20–82), and Caucasian (79.9%). The study protocol was
approved by the University of Michigan Medical Institutional Review Board; all data
were collected via online surveys between April 2009 and May 2010, and responses were
deidentified. For the present study, 56 cases were excluded due to missing FIQR data.
This study included clinical self-report measures that were used for the assessment of
external validity of the subgroups in the present study (see measures used for external
validation); random subsamples of around 250–280 participants were generated to answer
each self-reported measure.
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The other subsample consisted of 4986 adult FM patients who took part in a study
designed to examine the relationship between mindfulness facets and FM impact [21]. In
this study, the FM diagnosis was self-reported by participants, and the responses to the
questionnaires were given via an online survey, after Oregon Health & Science University
Institutional Review Board approval. No missing data were found in our main study
measure (FIQR). The survey asked about gender, age, marital status, and education level,
among other sociodemographic information. Participants represented all 50 states in the
US, with some participants residing in other countries (n = 289); these latter cases were
excluded in the present study. Most participants were women (96.6%) with a mean age of
52.2 (SD = 10.6, Range = 21–89), and their FM symptoms had been present for more than
10 years in most cases (74%). Almost half of the participants reported university studies
(47%), and 53% of the sample were not working when they were evaluated.
2.2. Study Measures
2.2.1. Measure Used for Cluster Derivation: The FIQR
The FIQR is the gold standard for evaluating functional status of patients with FM. It
consists of 21 items measuring the core symptoms and impact of FM in the last 7 days and
contains three subscales: Physical dysfunction (0–30), overall impact (0–20), and intensity
of the symptoms (0–50). Every item is rated using a Likert scale (0 = “lowest severity”
to 10 = “highest severity”). The global score is obtained by adding the three subscales
scores (0–100). The FIQR has high internal consistency (α = 0.91–0.95), good test-retest
reliability (r = 0.82), and construct validity [22]. The FIQR was completed by a total of
6280 respondents.
2.2.2. Measures Used for Clinical External Validation of the FIQR Profiles
The Brief Pain Inventory-short form (BPI-SF) [23] is a 9-item measure that assesses the
intensity and impact of pain. Pain intensity is assessed at its “worst”, “least”, “average”,
and “now”; for the present study, a composite of the four pain items was used as the mean
severity score (ranging from 0 = “no pain” to 10 = “pain as bad as one can imagine”). Pain
interference is scored as the mean of the 7 interference items and ranges from 0 (pain does
not interfere) to 10 (it completely interferes). The inventory presents strong psychometric
properties [24]. It was completed by 255 participants of the first subsample (4.1% of the
pooled sample).
The Hospital Anxiety and Depression Scale (HADS) [25] is a 14-item self-reported
scale developed to assess the presence of anxiety and depression symptoms during the
last 7 days. The total score ranges from 0 to 42, and each subscale (HADS-Anxiety and
HADS-Depression) includes 7 items whose scores range from 0 (lowest severity) to 21
(highest severity). This scale has shown sound psychometric properties [26]. The HADS
was completed by 285 participants of the first subsample (4.5% of the pooled sample).
The Multiple Ability Self-Report Questionnaire (MASQ) [27] is a 38-item questionnaire
that has been used to characterize perceived cognitive impairment (i.e., “fibrofog”) and is
commonly used to assess cognitive dysfunction in FM clinical trials [20]. The questionnaire
explores everyday performance in 5 domains: Language, visual-perceptual abilities, verbal
and visual memory, and attention/concentration. Each subscale contains 8 items, except
the visual-perceptual ability subscale, which contains 6. The items are rated on a 5-point
Likert scale (1 = almost never; 5 = almost always) regarding the frequency of specific
difficulties. The total score ranges from 38 to 190, where higher scores indicate more severe
perceived impairment [28]. The MASQ was completed by 252 participants of the first
subsample (4% of the pooled sample).
The Multidimensional Fatigue Inventory (MFI-20) [29] is a 20-item measure that
consists of 5 subscales: General fatigue, physical fatigue, activity, motivation, and mental
fatigue. Each item is scored in a 5-point Likert scale, and the score of each subscale ranges
from 4 to 20, with higher scores reflecting greater severity. The reliability and validity
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of this inventory is adequate. The MFI-20 was completed by 274 participants of the first
subsample (4.4% of the pooled sample).
The Medical Outcomes Study sleep scale (MOS-Sleep) [30] is a 12-item measure which
can be divided into 6 dimensions; however, for the present study, only the sleep problem
index (i.e., a summary score of 6 items) was used. Each of these 6 items is scored on
a Likert-scale (1 = all the time; 6 = none of the time). The score of the sleep problem
index ranges from 6 to 36, where higher scores indicate worse sleep functioning. The
MOS-Sleep presents strong psychometric properties [31]. This measure was completed by
266 participants of the first subsample (4.2% of the pooled sample).
2.3. Statistical Analyses
Clusters were established by means of exploratory hierarchical agglomerative cluster
analysis (HCA), using the Ward method to form clusters, which is the most widely used
method in similar studies. The software used for performing these analyses was SPSS v22.0
(SPSS Inc., Chicago, IL, USA). Following Pérez-Aranda et al.’s methodology [11], a latent
profile analysis (LPA) was computed to confirm the optimal number of subgroups. LPA is
a person-centered statistical technique that takes measurement error into account and, thus,
represents a potentially more statistically sophisticated approach [32]. We used MPlus v7.4
(Mñuthen & Múthen, Los Angeles, CA, USA) to compute LPA.
An ordinal regression analysis was carried out to determine the predicted cluster
membership [33]. For this analysis, FIQR items were used as independent variables and
the cluster category was taken as the dependent variable. The ordinal regression would
then estimate the probability of each cluster for every case, selecting the one with the
highest probability. Then, the Cohen’s kappa (k) coefficient was calculated to measure the
agreement between the predicted assigned subgroup and the originally assigned (k rule
of thumb: ≤ 0 = no agreement, 0.01–0.20 = none to slight, 0.21–0.40 = fair, 0.41–0.60 =
moderate, 0.61–0.80 = substantial, and 0.81–1.00 = almost perfect agreement) [34].
Between-group differences in sociodemographic data and the clinical measures were
analyzed in order to assess the external validity of the calculator-derived classification.
One-way ANOVAs or MANOVAs with Games-Howell post hoc tests were computed for
continuous variables (i.e., FIQR items and the scores of the rest of scales), and the chi
squared test was used for categorical data. The effect size in analyses of variance was
based on partial eta-squared (ηp2 rule of the thumb: 0.01 = small; 0.06 = medium; and
0.14 = large) (10), which can be interpreted as the proportion of variance in the dependent
variable that is attributable to each effect.
3. Results
3.1. Hierarchical Cluster Analysis
The HCA distributed the sample in 4 subgroups of patients with different levels of FM
severity, which accounted for 17.6%, 24.2%, 23.4%, and 34.7% of the sample, respectively.
The pairwise comparisons showed statistically significant differences between clusters
for all the FIQR items (all p values < 0.001), always following the same pattern: 1 <
2 < 3 < 4. Thus, the subgroups could be labelled as in a previous study [11]: “Mild–
moderate”, “moderate”, “moderate–severe”, and “severe” impact of FM. Figure 1 shows
the distribution of the FIQR items’ mean score for each calculator-derived cluster.
The level of agreement between the clusters obtained in the HCA and the ones
predicted by the calculator was substantial (k = 0.77). In this case, the predicted clusters
accounted for 11.6%, 35.9%, 23.9%, and 28.6% of the sample. Therefore, we decided to
retain the calculator-derived clusters for further analyses (external validity).
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3.2. Latent Profile Analysis
The LPA indicated that the four-profile solution fit our data better than the other
profile solutions (see Supplementary Table S1). Entropy values indicated that patients
were well classified in all class solutions overall. The LMR-LRT p values suggested that
the 5-class model was not superior to the 4-class model. Good discrimination between
classes was observed with high-average latent class probabilities for most likely latent
class membership (class 1 = 0.96; class 2 = 0.93; class 3 = 0.94; and class 4 = 0.95). The
four subgroups obtained with the LPA represented 11.8%, 23.5%, 36.2%, and 28.5% of the
sample, respectively. The pairwise comparisons showed statistically significant differences
between clusters for all the FIQR items (all p values < 0.001), always following the same
pattern: 1 < 2 < 3 < 4. The comparison between the two methods (HCA and LPA) showed
a substantial level of agreement (k = 0.73, p < 0.001). Subgroup 3 was the one with the
highest level of agreement (96.3%), followed by subgroup 4 (80.5%), subgroup 2 (73.2%),
and subgroup 1 (68.1%). Supplementary Figure S1 shows the distribution of the FIQR
items’ mean score for each profile.
3.3. Between-Cluster Differences in Sociodemographic and Clinical Variables
Table 1 presents the sociodemographic characteristics of the subgroups using the
calculator predicted cluster per each case. Differences between subgroups were observed
in age (p < 0.001), gender (χ2 = 17.01, p = 0.009), marital status (χ2 = 29.41, p = 0.001),
and years since FM diagnosis (F = 4.01, p = 0.007), although the effect sizes were small
(ηp2 < 0.006). In contrast, there was a large effect for differences in distribution across
clusters for education level, which was only assessed in the second sample (χ2 = 261.08,
p < 0.001).
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Table 1. Sociodemographic characteristics per Fibromyalgia Impact Questionnaire-Revised (FIQR) calculator-derived cluster.
Sociodemographic Characteristics Cluster 1 Cluster 2 Cluster 3 Cluster 4 p Value
Gender, N of females (%) 1038 (95.2%) 1466 (96.6%) 1447 (96.7%) 2118 (97.3%) 0.009
Age, M (SD) 53.30 (11.78) 52.77 (11.06) 51.81 (10.67) 51.34 (9.80) <0.001
Marital status, N of married (%) 623 (72.4%) 831 (72.1%) 750 (68.9%) 1049 (65.7%) 0.001
Education, N (%) <0.001
Less than high school 1 (0.1%) 1 (0.1%) 3 (0.3%) 5 (0.3%)
High school graduate 75 (8.7%) 96 (8.3%) 115 (10.6%) 252 (15.2%)
College/trade school 247 (28.7%) 402 (34.9%) 482 (44.3%) 789 (49.4%)
Bachelor’s degree 313 (36.4%) 409 (35.5%) 327 (30.1%) 420 (26.3%)
Postgraduate 224 (26%) 244 (21.2%) 161 (14.8%) 140 (8.8%)
Years of Fibromyalgia (FM)
diagnosis, M (SD) 12.59 (7.77) 12.15 (7.54) 11.70 (7.30) 11.58 (7.63) 0.007
Table 2 presents the results for all the self-reported measures using the predicted
cluster per each case. All of them presented statistically significant differences between
clusters with large effect sizes in all cases but three: For HADS-A and MASQ, the effect
size was medium (i.e., ηp2 between 0.06 and 0.14), and the HADS-D showed no differences
between clusters (p = 0.989). The pairwise comparisons showed the expected relation
between clusters (i.e., 1 < 2 < 3 < 4) in all the FIQR subscales and total score as well as in
the BPI. In the remaining outcomes, there can be observed a tendency towards this relation,
yet some of the pairwise comparisons did not present significant differences (i.e., MASQ,
HADS-A, MFI-20, and MOS-Sleep).
Table 2. Clinical outcomes per FIQR calculator-derived cluster.
Clinical Outcomes Cluster 1 Cluster 2 Cluster 3 Cluster 4 ηp2 Pairwise
FIQR
Physical dysf. 6.32 (3.50) 13.63 (3.21) 18.57 (2.58) 23.92 (2.85) 0.82 1 < 2 < 3 < 4
Overall impact 5.03 (3.22) 9.72 (3.58) 13.23 (3.21) 16.76 (2.20) 0.65 1 < 2 < 3 < 4
Symptom sev. 22.01 (6.53) 29.89 (5.02) 34.54 (4.36) 41.01 (4.20) 0.66 1 < 2 < 3 < 4
Total score 33.36 (9.47) 53.25 (6.02) 66.34 (4.95) 81.69 (7.14) 0.86 1 < 2 < 3 < 4
BPI
Severity 3.32 (1.53) 4.80 (1.31) 5.80 (1.11) 6.77 (1.15) 0.50 1 < 2 < 3 < 4
Interference 3.26 (1.63) 5.74 (1.35) 6.67 (1.46) 8.21 (1.05) 0.63 1 < 2 < 3 < 4
HADS
Anxiety 9.97 (3.51) 11.92 (4.55) 12.97 (4.39) 13.14 (3.32) 0.07 1 < 3, 4
Depression 7.29 (2.62) 7.38 (2.36) 7.38 (2.99) 7.23 (4.02) 0.00 -
MASQ 119.27 (5.97) 119.89 (5.14) 121.44 (6.81) 123.47 (7.64) 0.06 1, 2 < 4
MFI-20
General fatigue 16.41 (2.27) 17.67 (2.23) 18.72 (1.73) 19.34 (1.11) 0.23 1 < 2 < 3, 4
Physical fatigue 13.39 (4.48) 15.91 (2.90) 17.70 (2.37) 18.51 (1.80) 0.28 1 < 2 < 3, 4
Activity 12.34 (4.36) 13.89 (4.26) 15.71 (3.33) 17.17 (2.84) 0.18 1, 2 < 3 < 4
Motivation 12.03 (4.67) 14.32 (3.60) 15.77 (3.76) 17.01 (3.20) 0.16 1, 2 < 3, 4
Mental fatigue 10.94 (2.70) 14.03 (3.05) 14.97 (3.51) 16.47 (2.80) 0.24 1 < 2, 3 < 4
MOS-Sleep 19.43 (6.18) 23.87 (4.34) 25.09 (4.51) 26.90 (4.57) 0.21
1 < 2, 3
1, 2 < 4
Note: In bold, statistically significant results (p < 0.05). Score ranges (min-max) appear between brackets in the first column. FIQR:
Fibromyalgia Impact Questionnaire-Revised; BPI: Brief Pain Inventory; HADS: Hospital Anxiety and Depression Scale; MASQ: Multiple
Ability Self-Report Questionnaire; MFI-20: Multidimensional Fatigue Inventory; MOS-Sleep: Medical Outcomes Study sleep scale.
4. Discussion
The 4-cluster solution based on FIQR scores at item level obtained in a large Spanish
sample of patients with FM [11] seems promising due to its easily applicability in clinical
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practice, but it lacked cross-cultural validity. The present study fills this gap by replicating
the proposed classification in a large US sample of individuals with FM.
Due to its consideration as “gold standard” measure of functional status, the FIQR
has been increasingly used in FM research, not only as a clinical outcome, but also as a
possible measure of classification of FM subtypes. The main advantage of using this classi-
fication system is that it only requires one self-report measure that is not time consuming
(FIQR can be completed by patients in < 2 min), unlike previous studies that have used a
comprehensive battery of instruments and different biomarkers [12].
Nevertheless, this classification presents some limitations that need to be acknowl-
edged: (1) It only provides a general description of the functional impact of FM, but not
detailed information on other relevant variables (e.g., history of childhood maltreatment,
comorbidities, biological markers, personality traits). This lack of detail may be balanced
however, by the clinical efficiency offered by this relatively brief classification method.
(2) The studies that have used this method to classify FM patients have reported different
cluster solutions: While the Italian sample (N = 353) analyzed by Salaffi et al. [19] was
classified into 3 severity clusters, the Spanish sample (N = 946) analyzed by Pérez-Aranda
et al. [11] yielded 4 clusters. Considering the cultural and sociodemographic similarities
between the two samples, it is possible that the different results are due to the size of
the samples, i.e., hypothetically, a larger Italian sample would have been equally dis-
tributed in 4 clusters. It should be noted that other 4-cluster distributions of FM patients
exist [12,35–41], but used other measures for cluster derivation (e.g., clinical measures
related to FM symptomatology) reflecting 4 clusters of differing levels of global severity.
Overall, although men were underrepresented, our pooled study sample was repre-
sentative of the population of patients with FM, who are primarily female, middle-aged,
Caucasian, and have at least some college education. This pooled US sample used for
the present study was optimally classified in 4 subgroups according to the HCA and
confirmed by the LPA, as every FIQR subscale and the total score of the questionnaire
presented significant differences between clusters with a large effect size (i.e., ηp2 > 0.14),
always following the expected pattern: 1 < 2 < 3 < 4. Sociodemographic characteristics
presented some statistically significant differences between subgroups, such as age, gender,
or marital status, which should not be considered clinically significant in any case and
most likely attributable to the large sample size, as for instance, the proportion of women
in the 4 clusters ranged between 95.5% (cluster 1) and 97.4% (cluster 3), and ages ranged
between 51.48 (clusters 3 and 4) and 53.24 years old (cluster 1).
The education level did show a between-subgroup difference that should be noted:
According to our data, the level of education is inversely proportional to the FM severity.
While 49.4% of FM patients in subgroup 4 (i.e., “severe”) had completed primary education,
only 8.8% had post-graduate education; this proportion was notably higher in the other
subgroups (1 = 26%, 2 = 21.2%, 3 = 14.8%). This result calls for a discussion on the
sociodemographic profile of the FM patient; while it has been widely studied that FM affects
mainly middle-aged women, not so much attention has been directed to the economic
and educational profile of this population. Some previous studies have reported strong
negative correlations between low levels of education and FM severity [42–44]. In addition,
FM has been found to be more prevalent in people with low socioeconomic status in
countries like Brazil [45], Turkey [46], or Canada [47], and low income was reported as a
variable that increases the risk of suffering FM in a cohort study conducted in Finland [48].
There might be different coherent explanations for the effect of education on FM prevalence
and its severity, yet it seems reasonable to include among them the type of jobs that low-
educated people usually have access to (blue-collar workers), which are often physically
demanding; this, along with other variables (e.g., genetic vulnerability, stressors, and other
psychological comorbidities such as anxiety or depression), may trigger the dysregulation
of the central nervous system, responsible for the symptomatology of FM (e.g., hyperalgesia
and allodynia, among others) [2]. Additionally, those jobs are typically associated with
lower income, which is an objective obstacle for accessing private health insurances and
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useful health-resources such as yoga classes or psychotherapies that are usually out-of-
pocket costs in most countries [49].
Concerning external validity, the subgroups presented statistically significant dif-
ferences in pain, anxiety symptoms, perceived cognitive impairment, fatigue, and sleep
problems. Most of these differences presented a large effect size (ηp2 > 0.14), except for
anxiety and perceived cognitive impairment, which presented medium effect sizes. The
significant differences always followed the expected pattern (i.e., 1 < 2 < 3 < 4), although
in some cases there were no significant differences between some of the subgroups. Sur-
prisingly, the only variable that did not show any difference between subgroups was
depressive symptoms, as measured by the HADS-D, whose scores were relatively low
in all cases (i.e., ranging 7–8 out of 21), although participants in cluster 4 presented a
notably higher standard deviation than the rest. However, when analyzing the FIQR item
related to depressive symptomatology (item 16), significant differences were appreciated
between clusters in the expected direction (p < 0.001). This result is consistent with previous
findings, as depressive symptomatology has been reported to differ significantly among
FM subgroups in various studies, including those using the FIQR as cluster derivation
measure [11,13,35,37,39,50,51], for what it could be concluded that the HADS-D did not
measure with precision the depressive symptomatology of this subsample. In this regard,
some studies have indicated that the HADS does not differentiate well between depressive
and anxious symptoms, suggesting that subscale scores are not warranted and that only the
total score should be computed and reported [52]. Despite that counterintuitive result, and
considering that the rest of the secondary measures did present the expected significant
differences between clusters, a free online cluster calculator was created following the
path drawn by Pérez-Aranda et al. [11], to share the results of the present study so future
researchers can implement them to study how the clusters respond to different treatment
alternatives and further extend studies into the characterization of FM. This calculator can
be found as Supplementary Material.
The limitations of this study include, as stated previously, using only one measure for
cluster derivation (i.e., the FIQR), which implies some shortcomings compared to other
methods that include more measures. However, a comprehensive approach would be
unaffordable for real clinical practice, in the case clusters could be used for personalized
medicine. One of the major limitations in the present work was that diagnosis of FM was
self-reported and not provided by medical records or confirmed by a healthcare profes-
sional. Another shortcoming in this work is that we do not know whether participants were
under treatment at the time of the study. Another notable limitation of the present study
is the relatively low proportion of participants that completed the measures for external
validation, approximately a 4% of the pooled sample, which in the case of HADS-D was
clearly not representative of the FM population. Moreover, it should be considered that
the two samples conforming this study include a very low proportion of men with FM;
this is a common shortcoming of cluster studies conducted to date, as FM was believed to
affect mostly women. With the latest update of the diagnostic criteria from the American
College of Rheumatology, estimates indicate men should represent almost one third of FM
patients [53]. Furthermore, it is also known that fewer men respond to online recruitment
in general [54].
5. Conclusions
The present study supports validation of a 4-cluster distribution based on FIQR scores
for a large US sample of FM patients. The main challenge for future studies is now to test
how the different subgroups respond to the already validated interventions in the interest
of personalized medicine.
Supplementary Materials: The following are available online at https://www.mdpi.com/1660-4
601/18/1/247/s1, Figure S1: Latent profile class distribution, Table S1: Model fit for the 2–5 class
LPA solutions.
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